Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection

Journal of Infectious Diseases

Volumn 185, Issue 1, 2002, Pages 61-68

  Dybul, Mark ^a   Hidalgo, Bertha ^a   Chun, Tae Wook ^a   Belson, Michael ^a   Migueles, Stephen A ^a   Justement, Jesse S ^a   Herpin, Betsey ^a   Perry, Cheryl ^a   Hallahan, Claire W ^a   Davey, Richard T ^a   Metcalf, Julia A ^a   Connors, Mark ^a   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; EFAVIRENZ; INDINAVIR; INTERLEUKIN 2; LAMIVUDINE; NEVIRAPINE; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ADJUVANT CHEMOTHERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INTERMITTENT THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE COUNT; NEUROPATHY; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; VESTIBULAR DISORDER;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COCULTURE TECHNIQUES; DRUG SYNERGISM; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; INTERFERON TYPE II; INTERLEUKIN-2; LAMIVUDINE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; OXAZINES; PILOT PROJECTS; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE;

EID: 0036139572     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/338123     Document Type: Article

References (41)

1. + cell numbers and clinical staging
2. Early T-helper cell defects in HIV infection
3. + T cell proliferation and production of IFN-gamma in response to p24 antigen in HIV-infected individuals: Potential contribution of anergy to HIV-specific unresponsiveness
4. +T cell responses associated with control of viremia
5. Characterization of HIV-1-specific T-helper cells in acute and chronic infection
6. + T cell homeostasis and function in advanced HIV disease
7. Restoration of the immune system with anti-retroviral therapy
8. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy
9. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?
10. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
11. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy
12. + T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
13. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy
14. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy
15. Lymphocyte-proliferative responses to HIV antigens as a potential measure of immunological reconstitution in HIV disease
16. HAART in HIV-infected patients: Restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia
17. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection
18. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis
19. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir
20. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
21. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
22. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection
23. Immune control of HIV- 1 after early treatment of acute infection
24. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤ 250/μL CD4 T cells and undetectable plasma virus load
25. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: A randomized, controlled, multicenter study
26. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons
27. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease
28. Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens
29. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection: A preliminary study
30. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus
31. Interleukin-2 in combination with zidovudine and didanosine is able to maintain high levels of CD4 cells and undetectable HIV viraemia
32. Comparison between subcutaneous and intravenous interleukin-2 treatment in HIV disease
33. + T lymphocytes in interleukin-2-treated HIV-infected patients
34. Impaired function of circulating HIV-specific CD8 T cells in chronic human immunodeficiency virus infection
35. + T cells in HIV-infected progressors and long-term nonprogressors
36. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
37. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection
38. Allergen-stimulated interleukin-4 and interferon-gamma production in primary culture: Responses of subjects with allergic rhinitis and normal controls
39. Th1/Th2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens
40. Production by activated human T cells of interleukin 4 but not interferon-gamma is associated with elevated levels of serum antibodies to activating malaria antigens
41. +T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy